Hasta un 35% de sobreprecio habría pagado la Central de Abastecimiento del Sistema Nacional de Servicios de Salud (Cenabast), que intermedia la compra de medicamentos para consultorios y hospitales públicos. Ese fue uno de los puntos medulares del requerimiento de la Fiscalía Nacional Económica (FNE) en contra de los laboratorios Fresenius Kabi Chile, su filial Sanderson, y Biosano, por acordar un supuesto pacto para afectar el resultado de los concursos convocados entre 1999 y la primera mitad de 2013.
Featured News
FIFA Seeks to Toss Antitrust Case Over AI-Related Court Sanctions
Oct 7, 2026 by
CPI
Vail Resorts Directors Face Shareholder Suit Over Alleged Ski-Pricing Antitrust Failures
Oct 7, 2026 by
CPI
Anglo American Warns Brazil Nickel Mines Could Close If EU Blocks MMG Sale
Oct 7, 2026 by
CPI
Emera, Canadian Utilities Deal Would Create C$72 Billion North American Energy Giant
Oct 7, 2026 by
CPI
FTC Targets Booking Holdings in Hotel-Booking Advertising Probe
Oct 7, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – National Security
Sep 22, 2026 by
CPI
National Security in U.S. Antitrust Enforcement: Toward a More Disciplined Framework
Sep 22, 2026 by
Rod Rosenstein & Timothy Finley
The Department of War’s M&A Review Guidance: What Companies in the Defense Industry Need to Know
Sep 22, 2026 by
Eric Stocking & Paul Ney
National Security, Resilience and the Boundaries of Merger Control
Sep 22, 2026 by
Beatriz Marques
National Security and Competition: Building Resilient Telecommunications Networks
Sep 22, 2026 by
Roslyn Layton